

Comparative Antidiabetic, Hypolipidemic, and Antioxidant Properties of *Phyllanthus niruri* in Normal and Diabetic Rats

Jasmin H. Bavarva and A.V.R.L. Narasimhacharya

Department of Biosciences, Sardar Patel University, Gujarat, India

Abstract

The antidiabetic, hypolipidemic, and antioxidant properties of *Phyllanthus niruri* (L) (Euphorbiaceae) were compared in normal, insulin-dependent diabetes mellitus (IDDM), and non-insulin-dependent diabetes mellitus (NIDDM) animals through evaluating the effects on carbohydrate and lipid metabolism and antioxidant activities. The alcohol extract of *Phyllanthus niruri* produced significant antidiabetic effect in IDDM alone but lowered lipid profiles and improved body antioxidant activities in both IDDM and NIDDM animals. This investigation revealed that the lipid-lowering effect of *Phyllanthus niruri* is independent from its antidiabetic action.

Keywords: Antidiabetic, hypolipidemic, IDDM, NIDDM, *Phyllanthus niruri*.

Introduction

Diabetes mellitus (DM) is one of the major health problems affecting a significant portion of the population worldwide (Zimmet et al., 2001). DM is classified as insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM). Both IDDM and NIDDM share most common symptoms such as long-term hyperglycemia leading to macrovascular and microvascular complications (Attele et al., 2002). It has been established that hyperglycemia is the principal cause of diabetic complications (Brownlee 2001). Although glucose levels are controlled by medication, atherosclerosis can still develop in diabetic

patients (Steinberg et al., 2000), which is a potent independent risk factor for cardiovascular disease (CVD) (American Diabetes Association, 1998). People with diabetes exhibit a pattern of dyslipidemia characterized by elevated triglycerides and low levels of high-density lipoprotein cholesterol (HDL-C) (Resnick et al., 2002). In addition, diabetic conditions increase oxidative stress (Glugliano et al., 1996) and deplete antioxidant levels in the body (Fonseca et al., 2004). Therefore, improvement in glucose, lipid, and antioxidant profiles could be useful in management of diabetes and its complications.

Phyllanthus niruri L. (Euphorbiaceae) (syn. *Phyllanthus amarus* Schum & Thonn) is a traditionally well-known plant in India for its Ayurvedic and folklore medicinal uses such as in the treatment of jaundice (Raja Reddy, 1988), hepatitis, dysentery, and irritating sores (Reddy et al., 1993). The aqueous and methanol extracts of the leaves of this plant were reported to be hypoglycemic (Ramakrishnan et al., 1982; Raphael et al., 2002), hypotensive and hypoglycemic in human hypertensive (and secondarily diabetic) subjects but was found to be neither hypercholesterolemic nor hypocholesterolemic (Srividya & Periwal, 1995). However, Khanna et al. (2002) reported that *Phyllanthus niruri* lowers the serum lipid levels in hyperlipemic rats and the antioxidant activity of this plant has been demonstrated *in vitro* (Raphael et al., 2002). These reports, however, pertain to alloxan-induced diabetic animals, hypertensive human subjects, hyperlipemic animals, and *in vitro* observations. Besides, the aqueous extracts of *P. amarus* were shown to enhance the clearance of oral glucose load though they did not

Accepted: May 4, 2007.

Address correspondence to: Dr. A.V. R. L. Narasimhacharya, Professor, Department of Biosciences, Sardar Patel University, Vallabh Vidyanagar-388 120, Gujarat, India; E-mail: n.bs@spu.ernet.in, narasimhacharya@yahoo.com

lower fasting blood glucose (FBG) in normal albino rabbits (Moshi et al., 1997) but were ineffective in lowering either FBG or postprandial blood glucose levels in NIDDM subjects (Moshi et al., 2001). As no reports are available with reference to comparative studies on the effect(s) of *Phyllanthus nirurion* on carbohydrate, lipid metabolism, and antioxidant activity in IDDM and NIDDM subjects, a comparative evaluation of antidiabetic, hypolipidemic, and antioxidant properties of *Phyllanthus niruri* in normal, IDDM, and NIDDM animals was undertaken.

Materials and Methods

Collection and extract preparation

The young leaves of the plant *Phyllanthus niruri* L. were collected from the university's botanical garden and authenticated by Dr. A.S. Reddy, Department of Biosciences, Sardar Patel University (voucher specimen no. JHB-01). Shade-dried leaves were powdered and extracted with 95% ethanol. The extract (PnIE) was filtered, dried at room temperature (yield 13.3% w/w), and the residue was stored at 4°C for later use.

Animals

Male Charles Foster rats were used for the current study. Animals were housed in polypropylene cages and maintained under ambient room temperature. They were fed standard pellet diet (Pranav Agro Ltd., Pune, India) and water *ad libitum*. The institutional animal ethics committee approved the study.

Induction of diabetes

Insulin-dependent diabetes mellitus

Rats weighing 200–250 g were fasted overnight and then given a single intraperitoneal (i.p.) injection of alloxan monohydrate (120 mg/kg b.w., Loba Chemie, Mumbai, India) dissolved in normal saline. Induction of diabetic condition was confirmed by FBG estimation (>140 mg/dL) over a period of 2 weeks.

Non-insulin-dependent diabetes mellitus

The model was developed according to the description of Bonner-Weir et al. (1981). Males aged 48 ± 2 h were injected (i.p.) with streptozotocin (Sisco Research Laboratories, Mumbai, India) in citrate buffer (pH 4.5) at a dose of 100 mg/kg b.w. The animals showing FBG levels >140 mg/dL after 12 weeks were considered as diabetic animals.

Experimental procedure

For the experiment, 48 rats were used (16 normal, 16 IDDM, and 16 NIDDM). Six groups of eight animals each were divided as follows. Group I: normal, vehicle-administered animals; group II: normal, PnIE-administered animals; group III: IDDM, vehicle-administered animals; group IV: IDDM, PnIE-administered animals; group V: NIDDM, vehicle-administered animals; and group VI: NIDDM, PnIE-administered animals.

Treatment was given at a dose of 300 mg/kg b.w. per day in 1 mL of 2% (v/v) Tween 80 suspension for 4 weeks by oral route. Control animals received equal volume of vehicle (1 mL of 2% Tween 80) only. At the end of the experimental period, the animals were deprived of food overnight and sacrificed under mild anesthesia; blood and liver tissues were collected and analyzed immediately.

Oral glucose tolerance test

Two days before the termination of the experiment, the oral glucose tolerance test (OGTT) was performed to assess the sensitivity to high glucose load. For this purpose, overnight-fasted rats were fed orally 2 g glucose/kg b.w. Blood was collected at 0-, 60-, and 120-min intervals from orbital sinus for glucose estimation.

Analytical methods

Plasma glucose levels were measured by the *o*-toluidine method (Webster et al., 1971), hepatic glycogen was extracted with 30% KOH, and the yield was determined by anthrone-sulfuric acid method (Seifter et al., 1950). Plasma cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were estimated by ferric perchlorate-sulfuric acid and glycerol-3-phosphate: O₂ 2-oxidoreductase (GPO) methods, respectively (Wybenga et al., 1970; McGown et al., 1983). Low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), and atherogenic index (AI) were calculated (Friedwald et al., 1972). The hepatic hexokinase (EC 2.7.1.1) was determined following the methods prescribed by Brandstup et al. (1957). The hepatic lipids were extracted (Folch et al., 1957) and used for the estimation of total cholesterol and triglyceride content (Wybenga et al., 1970; McGown et al., 1983). The peroxidation product, thiobarbituric acid reactive substances (TBARS), was determined by the method of Niehaus & Samuelsson (1968). Activities of antioxidant enzymes superoxide dismutase (EC 1.15.1.1) and catalase (EC 1.11.1.6) were estimated according to the methods described by Kakkar et al. (1984) and Aebi (1974), respectively.

Statistical analysis

Data are presented as mean \pm SEM. One-way analysis of variance (ANOVA) with Tukey's significant difference post hoc test was used to compare differences among groups. Data were statistically handled by SPSS statistical software, version 10. p values < 0.05 were considered as statistically significant.

Results

Both IDDM and NIDDM control animals registered significantly higher plasma glucose levels ($p < 0.001$). A significant reduction in plasma glucose level was noted only in PnIE-administered IDDM animals ($p < 0.001$). However, both IDDM and NIDDM animals registered significant reduction in TC, TG, LDL-C, VLDL-C, and AI and increases in HDL-C levels with PnIE administration when compared with vehicle-administered control groups (Tables 1 and 2).

The hepatic glycogen content of IDDM and NIDDM control animals declined significantly ($p < 0.001$). The IDDM animals alone registered a significant rise in hepatic glycogen level ($p < 0.001$) with PnIE administration although both NIDDM and normal groups revealed a small increase in hepatic glycogen content upon PnIE administration. The PnIE treatment to IDDM and NIDDM animals caused a significant decline in hepatic TC and TG levels (Tables 1 and 2).

Both IDDM and NIDDM controls registered significant decline in hexokinase activity ($p < 0.001$; $p < 0.01$). The hexokinase activity increased significantly in the

PnIE-administered IDDM group alone ($p < 0.001$) (Tables 1 and 2).

The PnIE treatment to IDDM and NIDDM animals decreased TBARS significantly ($p < 0.01$, $p < 0.05$, respectively) and caused a significant increase in catalase activity ($p < 0.01$, $p < 0.05$, respectively). However, SOD activity remained more or less unaltered in these groups (Tables 1 and 2).

A marked reduction in plasma glucose level occurred in the PnIE-treated IDDM group at 120 min compared with its counterpart. However, no improvements were found in NIDDM and normal animals (Fig. 1).

Discussion

In the current study, a significant increase in fasting blood glucose and decreases in hepatic glycogen levels and hexokinase activity was found in both untreated IDDM and NIDDM animals. PnIE administration caused a significant reduction in plasma glucose levels, increased hepatic glycogen content, and heightened the hepatic hexokinase activity in IDDM animals alone. Further, these animals also exhibited a marked improvement in glucose tolerance. The pronounced hypoglycemic effect of PnIE in IDDM animals could be due to either its insulin-like activity or its stimulatory effect on insulin. On the other hand, the lack of hypoglycemic activity of PnIE in NIDDM animals could be due to its inability to decrease the insulin resistance in these animals (Kergoat & Portha, 1985; Santosh et al., 2003). This lack of hypoglycemic activity of PnIE in NIDDM animals is reflected in their poor glucose tolerance.

Table 1. Effect of PnIE on various biochemical parameters in IDDM rats.

Parameters	Normal control	Normal PnIE-treated	IDDM control	IDDM PnIE-treated
Glucose ^a	103.73 \pm 4.68	99.41 \pm 5.02 ^{NS} (-4)	217.50 \pm 16.94*** (+110)	147.49 \pm 5.20*** (-32)
Hepatic glycogen ^b	21.31 \pm 0.78	22.42 \pm 0.79 ^{NS} (+5)	6.11 \pm 0.37*** (-71)	12.73 \pm 0.52*** (+108)
Hepatic hexokinase ^c	7.87 \pm 0.24	7.82 \pm 0.30 ^{NS} (-1)	4.22 \pm 0.24*** (-46)	5.91 \pm 0.38*** (+40)
TC ^a	109.95 \pm 3.25	114.50 \pm 4.06 ^{NS} (+4)	153.81 \pm 4.82*** (+40)	114.12 \pm 3.35*** (-26)
TG ^a	88.40 \pm 4.48	93.53 \pm 4.56 ^{NS} (+6)	159.34 \pm 6.22*** (+80)	124.96 \pm 5.77*** (-22)
LDL-C ^a	24.97 \pm 3.96	22.58 \pm 6.33 ^{NS} (-10)	87.35 \pm 4.88*** (+250)	35.22 \pm 5.01*** (-60)
VLDL-C ^a	17.67 \pm 2.53	18.70 \pm 2.58 ^{NS} (+6)	31.86 \pm 3.51*** (+80)	24.98 \pm 3.26*** (-22)
HDL-C ^a	67.30 \pm 2.20	73.22 \pm 6.32 ^{NS} (+9)	34.59 \pm 1.20*** (-49)	53.90 \pm 3.30** (+56)
AI	1.64 \pm 0.02	1.64 \pm 0.16 ^{NS} (0)	4.47 \pm 0.54*** (+173)	2.16 \pm 0.39*** (-52)
Hepatic TC ^b	5.78 \pm 0.22	4.76 \pm 0.47 ^{NS} (-18)	6.64 \pm 0.17 ^{NS} (+15)	5.53 \pm 0.10* (-17)
Hepatic TG ^b	10.93 \pm 0.45	10.77 \pm 0.17 ^{NS} (-1)	12.31 \pm 0.14* (+13)	10.60 \pm 0.31*** (-14)
TBARS ^d	0.757 \pm 0.05	0.754 \pm 0.03 ^{NS} (0)	0.939 \pm 0.06* (+24)	0.622 \pm 0.03** (-34)
SOD ^c	3.45 \pm 0.14	3.45 \pm 0.16 ^{NS} (0)	3.15 \pm 0.10 ^{NS} (-9)	3.47 \pm 0.14 ^{NS} (+10)
Catalase ^e	65.28 \pm 4.47	68.47 \pm 6.81 ^{NS} (+5)	33.73 \pm 4.29*** (-48)	58.12 \pm 2.93** (+72)

Values are mean \pm SEM of eight rats. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, NS (non-significant).

PnIE-treated group was compared with respective vehicle-treated group. IDDM control was compared with normal control. Values in parentheses represent the percent change.

Units: ^amg/dL; ^bmg/g; ^cU/mg protein; ^dmM/100 g; ^enM H₂O₂ decomposed/s per g tissue.

Table 2. Effect of PnIE on various biochemical parameters in NIDDM rats.

Parameters	Normal control	Normal PnIE-treated	NIDDM control	NIDDM PnIE-treated
Glucose ^a	103.73 ± 4.68	99.41 ± 5.02 ^{NS} (-4)	200.66 ± 6.29 ^{***} (+93)	168.58 ± 11.32 ^{NS} (-16)
Hepatic glycogen ^b	21.31 ± 0.78	22.42 ± 0.79 ^{NS} (+5)	8.62 ± 0.22 ^{***} (-60)	9.74 ± 0.41 ^{NS} (+13)
Hepatic hexokinase ^c	7.87 ± 0.24	7.82 ± 0.30 ^{NS} (-1)	6.37 ± 0.14 ^{**} (-19)	6.81 ± 0.18 ^{NS} (+10)
TC ^a	109.95 ± 3.25	114.50 ± 4.06 ^{NS} (+4)	150.76 ± 1.58 ^{***} (+37)	131.19 ± 2.66 ^{**} (-13)
TG ^a	88.40 ± 4.48	93.53 ± 4.56 ^{NS} (+6)	156.62 ± 3.94 ^{***} (+77)	126.41 ± 6.13 ^{**} (-19)
LDL-C ^a	24.97 ± 3.96	22.58 ± 6.33 ^{NS} (-10)	75.71 ± 1.99 ^{***} (+203)	54.53 ± 2.30 [*] (-28)
VLDL-C ^a	17.67 ± 2.53	18.70 ± 2.58 ^{NS} (+6)	31.31 ± 2.23 ^{***} (+77)	25.28 ± 3.47 ^{**} (-19)
HDL-C ^a	67.30 ± 2.20	73.22 ± 6.32 ^{NS} (+9)	36.72 ± 0.50 ^{***} (-45)	51.53 ± 1.12 [*] (+40)
AI	1.64 ± 0.02	1.64 ± 0.16 ^{NS} (0)	3.34 ± 0.25 ^{***} (+104)	2.62 ± 0.15 ^{**} (-22)
Hepatic TC ^b	5.78 ± 0.22	4.76 ± 0.47 ^{NS} (-18)	6.57 ± 0.10 ^{NS} (+14)	5.22 ± 0.16 ^{**} (-21)
Hepatic TG ^b	10.93 ± 0.45	10.77 ± 0.17 ^{NS} (-1)	13.13 ± 0.18 ^{***} (+20)	11.87 ± 0.12 [*] (-10)
TBARS ^d	0.757 ± 0.05	0.754 ± 0.03 ^{NS} (0)	0.939 ± 0.06 [*] (-24)	0.699 ± 0.05 [*] (-26)
SOD ^c	3.45 ± 0.14	3.45 ± 0.16 ^{NS} (0)	3.23 ± 0.10 ^{NS} (-6)	3.48 ± 0.27 ^{NS} (+8)
Catalase ^e	65.28 ± 4.47	68.47 ± 6.81 ^{NS} (+5)	35.52 ± 2.75 ^{***} (-45)	56.11 ± 3.77 [*] (+58)

Values are mean ± SEM of eight rats. *p < 0.05, **p < 0.01, ***p < 0.001, NS (non-significant).

PnIE-treated group was compared with respective vehicle-treated group. NIDDM control was compared with normal control. Values in parentheses represent the percent change.

Units: ^amg/dL; ^bmg/g; ^cU/mg protein; ^dmM/100 g; ^enM H₂O₂ decomposed/s per g tissue.

Both IDDM and NIDDM control animals exhibited marked increases in plasma and hepatic lipid profiles along with decreased HDL-C levels. Diabetes is associated with increased plasma and tissue cholesterol and triglyceride levels with lowered HDL-C profile (Glasgow et al., 1981; Goodman et al., 1982; Kudchodkar et al., 1988). Currently, PnIE administration to both IDDM and NIDDM animals caused a significant decline in both serum and hepatic lipid levels and increased the HDL-C levels. The significant decreases in LDL-C and increases in HDL-C levels in PnIE-administered IDDM and NIDDM animals on the other hand indicate the altered lipid metabolism under the influence of PnIE that are similar to the reported decline in LDL-C and elevation of HDL-C profiles in hyperlipemic rats treated with *Phyllanthus niruri* extract (Khanna et al., 2002). Consequent to lowered plasma lipid profiles, both PnIE-administered IDDM and NIDDM animals registered

a significant decrease in atherogenic index. Thus, while the lipid-lowering activity of PnIE appeared to be common to both IDDM and NIDDM animals, the hypoglycemic activity of PnIE is restricted to the IDDM animals alone even with a 4-week administration of PnIE (300 mg/kg b. w. per day). In this context, it is pertinent to note here that a 1-week treatment with *P. amarus* extract (12.5 g% dose) could not lower both FBG and postprandial blood glucose in NIDDM patients (Moshi et al., 2001) although a similar dose of extract (0.1 and 1.0 g/kg b. w.) could enhance the clearance rate of oral glucose load from blood without significantly affecting FBG levels in rabbits (Moshi et al., 1997). The stem bark extract of a related species of the genus *Phyllanthus* (i.e., *P. sellowianus*), however, was found to significantly reduce the blood glucose level in streptozotocin-induced diabetic (IDDM) mice at a dose of 200 mg/kg b. w. (Hnatyszyn et al., 2002). It is therefore evident that *P. niruri* (*P. amarus*) is ineffective in NIDDM with reference to maintenance of plasma glucose levels.

Chronic hyperglycemia induces lipid peroxidation, overproduction of superoxides, and produces oxidative stress (Nakakimura & Mizuno, 1980; Baynes 1991; Gugliano et al., 1996; Maxwell et al., 1997). Both IDDM and NIDDM groups registered increased TBARS, a marker of lipid peroxidation (24% increases over controls), and the PnIE administration significantly decreased the level of TBARS in these groups. SOD and catalase are known to be important antioxidant enzymes that catalyze superoxide radicals and reduce peroxides, respectively (Eriksson & Borg, 1991). Although the induction of diabetes significantly reduced the hepatic catalase activity in both diabetic groups,




Figure 1. Effect of PnIE on oral glucose tolerance test.

the SOD activity declined only marginally. Oral administration of PnIE to both IDDM and NIDDM animals significantly increased the catalase activity accompanied by a small increase in SOD activity. The activities of these enzymes in normal animals on the other hand did not register any changes upon PnIE administration.

Thus, our study shows that PnIE is both hypoglycemic and hypolipidemic in IDDM animals and predominately hypolipidemic in NIDDM animals. However, PnIE exhibited its antiperoxidative and antioxidant activities in both experimental diabetic groups. The effects of PnIE on normal animals were neither hypoglycemic nor hypolipidemic but appeared to maintain the euglycemic and eulipidemic status of these animals. Further investigation in a dose-dependent manner is in progress.

Acknowledgments

The financial assistance in the form of a research fellowship to J.H.B. from the Puri Foundation, Gandhinagar, Gujarat, India, is gratefully acknowledged.

References

- Aebi H (1974): Catalase. In: Bergmeyer HU, ed., *Methods of Enzymatic Analysis*. New York, Academic Press, pp. 673–684.
- American Diabetes Association (1998): Economic consequences of diabetes mellitus in the US in 1997. *Diabetes Care* 21: 296–309.
- Attele AS, Zhou YP, Xia JT, Wu JN, Zhang L, Dey L, Pugh W, Rue PA, Polonsky KS, Yuan CS (2002): Antidiabetic effects of *Panax ginseng* berry extract and the identification of an effective component. *Diabetes* 51: 1851–1858.
- Baynes JW (1991): Role of oxidative stress in development of complications in diabetes. *Diabetes* 40: 405–412.
- Bonner-Weir S, Trent DF, Honey RN, Weir GC (1981): Response of neonatal rat islets to streptozotocin. Limited β cell regeneration and hyperglycemia. *Diabetes* 30: 64–69.
- Brandstap N, Kirk JE, Bruni C (1957): Determination of hexokinase in tissues. *J Gerontol* 12: 166–171.
- Brownlee M (2001): Biochemistry and molecular cell biology of diabetic complications. *Nature* 414: 813–820.
- Eriksson UJ, Borg LAH (1991): Protection by free oxygen radical scavenging enzymes against glucose-induced embryonic malformation *in vitro*. *Diabetologia* 34: 325–331.
- Folch J, Lees MS, Stanley GH (1957): A simple method for the isolation and purification of total lipids from animal tissues. *J Biol Chem* 226: 497–509.
- Fonseca V, Desouza C, Asnani S, Jialal I (2004): Nontraditional risk factors for cardiovascular disease in diabetes. *Endocr Rev* 25(1): 153–175.
- Friedwald WT, Levy RT, Fredrickson DS (1972): Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 18: 499–502.
- Glasgow AM, August GP, Hung W (1981): Relationship between control and serum lipids in juvenile onset diabetes. *Diabetes Care* 4: 76–80.
- Glugliano D, Ceriello A, Paolissa G (1996): Oxidative stress and diabetic vascular complications. *Diabetes Care* 19: 257–267.
- Goodman MW, Michels LD, Keane WF (1982): Intestinal and hepatic cholesterol synthesis in the alloxan diabetic rats. *Proc Soc Exp Biol Med* 170: 286–290.
- Hnatyszyn O, Mino J, Ferraro G, Acevedo C (2002): The hypoglycemic effect of *Phyllanthus sellowianus* fractions in streptozotocin induced diabetic mice. *Phytomedicine* 9: 556–559.
- Kakkar P, Das B, Viswanathan PN (1984): A modified spectrophotometric assay of superoxide dismutase. *Indian J Biochem Biophys* 21: 130–132.
- Kergoat M, Portha B (1985): *In vivo* hepatic and peripheral insulin sensitivity in rats with non-insulin-dependent diabetes induced by streptozotocin. Assessment with the insulin-glucose clamp technique. *Diabetes* 34: 1120–1126.
- Khanna AK, Rizvi F, Chander R (2002): Lipid lowering activity of *Phyllanthus niruri* in hyperlipaemic rats. *J Ethnopharmacol* 82: 19–22.
- Kudchodkar BJ, Lee JC, Lee SM, DiMareo NM, Lacko AG (1988): Effect on cholesterol homeostasis in diabetic rats. *J Lipid Res* 29: 1272–1287.
- Maxwell SRJ, Thomson H, Sandler D, LeGuen C (1997): Poor glycaemic control is associated with reduced serum free radical scavenging (antioxidant) activity in non-insulin dependent diabetes mellitus. *Ann Clin Biochem* 34: 638–644.
- McGown MW, Artiss JD, Strandberg DR, Zak B (1983): A peroxidase-coupled method for the colorimetric determination of serum triglycerides. *Clin Chem* 29: 538–542.
- Moshi MJ, Lutale JJK, Rimoy GH, Abbas ZG, Josiah RM, Swai ABM (2001): The effect of *Phyllanthus amarus* aqueous extract on blood glucose in non-insulin dependent diabetic patients. *Phytother Res* 15: 577–580.
- Moshi MJ, Uiso FC, Mahunnah RLA, Malele SR, Swai ABM (1997): A study of the effect of *Phyllanthus amarus* extracts on blood glucose in rabbits. *Pharm Biol* 35: 167–173.
- Nakakimura H, Mizuno K (1980): Studies on lipid peroxidation in biological systems II. Hyperlipoperoxidemia in mice induced by alloxan. *Chem Pharm Bull* 28: 2207–2211.

- Niehaus WG Jr, Samuelsson B (1968): Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation. *Eur J Biochem* 6: 126–130.
- Raja Reddy K (1988): Folk medicine from Chittoor District, Andhra Pradesh, India, used in the treatment of jaundice. *Int J Crude Drug Res* 26: 127–140.
- Ramakrishnan PN, Murugan R, Palanichamy S, Muruges N (1982): Oral hypoglycemic effect of *Phyllanthus niruri*. *Indian J Pharm Sci* 44: 10–12.
- Raphael KR, Sabu MC, Kuttan R (2002): Hypoglycemic effect of methanolic extract of *Phyllanthus amarus* Schum & Thonn on alloxan induced diabetes mellitus in rats and its relation with antioxidant potential. *Indian J Exp Biol* 40: 905–909.
- Reddy MB, Bryan HH, Lance CJ, McMillan RT Jr (1993): A survey of plant crude drugs of Anantapur district, Andhra Pradesh, India. *Econ Bot* 47: 79–88.
- Resnick HE, Howard BV (2002): Diabetes and cardiovascular disease. *Annu Rev Med* 53: 245–267.
- Santosh LV, Rajani M, Goyal RK (2003): Comparative antidiabetic activity of different fractions of *Enicostemma littorale* Blume in streptozotocin induced NIDDM rats. *Orient Pharm Exp Med* 3(4): 196–204.
- Seifter S, Dayton S, Noyic B, Muntwyler E (1950): Estimation of glycogen with anthrone reagent. *Arch Biochem* 25: 191–200.
- Srividya N, Periwai S (1995): Diuretic, hypotensive and hypoglycaemic effects of *Phyllanthus amarus*. *Indian J Exp Biol* 33: 861–864.
- Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD (2000): Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. *Diabetes* 49: 1231–1238.
- Webster WW, Stinson SF, Wong WH (1971): Manual procedure for direct microassay of serum glucose by *o*-toluidine, and its adaptation to the SMA 12/60 autoanalyser. *Clin Chem* 17: 1050–1054.
- Wybenga DR, Pileggi VJ, Dirstine PH, Di Giorgio J (1970): Direct manual determination of serum total cholesterol with a single stable reagent. *Clin Chem* 16: 980–984.
- Zimmet P, Alberti KGMM, Shaw J (2001): Global and societal implications of the diabetes epidemic. *Nature* 414: 782–787.

Copyright of *Pharmaceutical Biology* is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.

Copyright of *Pharmaceutical Biology* is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.

Copyright of *Pharmaceutical Biology* is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.